However, the FCN2 variant was found in three primary disease subgroups (BC, MS, Other) and in PML cases exposed to one of three different drugs (1 dimethyl fumarate case, 2 natalizumab cases, and 2 rituximab cases; see Supplementary Table 8). Here, FCN2 is linked to myeloid sarcoma.